Edition:
United Kingdom

China Biologic Products Holdings Inc (CBPO.OQ)

CBPO.OQ on NASDAQ Stock Exchange Global Select Market

74.68USD
8:59pm GMT
Change (% chg)

$-1.53 (-2.01%)
Prev Close
$76.21
Open
$76.65
Day's High
$77.73
Day's Low
$74.46
Volume
32,649
Avg. Vol
99,758
52-wk High
$107.32
52-wk Low
$60.09

Latest Key Developments (Source: Significant Developments)

David Gao Confirms Lawsuit Against China Biologic Products
Wednesday, 29 Aug 2018 

Aug 29 (Reuters) - David Gao :DAVID GAO CONFIRMS LAWSUIT AGAINST CHINA BIOLOGIC PRODUCTS TO PROTECT SHAREHOLDERS’ BEST INTERESTS.DAVID GAO - CONFIRMED FILED LAWSUIT AGAINST CO RELATED TO PRIVATE PLACEMENT OF SHARES TO SELECT INVESTOR GROUP.  Full Article

China Biologic Responds To Lawsuit Filed In Cayman Islands By Former Chairman
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC RESPONDS TO LAWSUIT FILED IN CAYMAN ISLANDS BY FORMER CHAIRMAN.CHINA BIOLOGIC PRODUCTS HOLDINGS - ISSUED STATEMENT IN RESPONSE TO LAWSUIT FILED AGAINST COMPANY IN CAYMAN ISLANDS BY DAVID (XIAOYING) GAO.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - CLOSED 3.8 MILLION SHARES IN PRIVATE PLACEMENT & WILL CLOSE REMAINING IN ACCORDANCE WITH TRANSACTION AGREEMENTS.  Full Article

Investor Group Issues Statement Following China Biologic’s Private Placement Of Shares
Friday, 24 Aug 2018 

Aug 24 (Reuters) - Investor Group::LEADING INVESTOR GROUP ISSUES STATEMENT FOLLOWING CHINA BIOLOGIC’S DILUTIVE PRIVATE PLACEMENT OF SHARES.INVESTOR GROUP SAYS IN RELATION TO CHINA BIOLOGIC'S REJECTION OF ITS PROPOSAL, "WILL EVALUATE ALL OPTIONS, INCLUDING LEGAL ACTION".  Full Article

PW Medtech Group To Purchase 800,000 China Biologic Products Shares For $80.72 Mln
Friday, 24 Aug 2018 

Aug 24 (Reuters) - PW Medtech Group Ltd <1358.HK>::CO TO PURCHASE 800,000 CHINA BIOLOGIC PRODUCTS (CBPO) SHARES, AT A PRICE OF US$100.9 PER CBPO SHARE.AGGREGATE PURCHASE PRICE FOR CBPO SHARES SHALL BE $80.72 MILLION.  Full Article

China Biologic Announces Receipt Of Competing Non-Binding Acquisition Proposal
Tuesday, 21 Aug 2018 

Aug 21 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES RECEIPT OF COMPETING NON-BINDING ACQUISITION PROPOSAL.CHINA BIOLOGIC PRODUCTS HOLDINGS INC - BOARD IS REVIEWING AND EVALUATING CONSORTIUM PROPOSAL AND CITIC PROPOSAL AND NO DECISIONS HAVE BEEN MADE.  Full Article

China Biologic Products Q2 Earnings Per Share $0.83
Friday, 3 Aug 2018 

Aug 3 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.17.Q2 EARNINGS PER SHARE $0.83.Q2 SALES ROSE 34.8 PERCENT TO $120.4 MILLION.SAYS REVISES FULL YEAR FINANCIAL FORECAST.IS MAKING A DOWNWARD REVISION TO ITS FULL YEAR 2018 FORECAST.EXPECTS FY2018 NON-GAAP ADJUSTED INCOME FROM OPERATIONS TO INCREASE BY 0% TO 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS-"Q2 CONTINUED TO BE CHALLENGING DUE TO ONGOING IMPACT OF REGULATORY CHANGES & INTENSIFIED COMPETITION IN CHINA'S HEALTHCARE MARKET".SEES FY2018 NON-GAAP ADJUSTED NET INCOME TO DECREASE BY 2% TO 4% IN RMB TERMS.CHINA BIOLOGIC-2018 FORECAST WAS LOWERED TO ACCOUNT FOR WORSE-THAN-EXPECTED RESULTS FOR H1 2018 AND ONGOING CHALLENGING OUTLOOK IN H2 OF YEAR.CHINA BIOLOGIC PRODUCTS HOLDINGS-FOR H2, EXPECT "REGULATORY HEADWINDS AND MARKET COMPETITIVE DYNAMICS TO PERSIST", WHICH WILL IMPACT GUIDANCE FOR YEAR.  Full Article

China Biologic Says Excluding Financial Results Of Tianxinfu, Q1 Sales To Grow About 2% In RMB
Tuesday, 24 Apr 2018 

April 24 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC PRODUCTS HOLDINGS - EXCLUDING FINANCIAL RESULTS OF TIANXINFU, TOTAL SALES IN Q1 OF 2018 EXPECTED TO GROW ABOUT 2% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS - INCLUDING TIANXINFU'S CONTRIBUTION, TOTAL SALES FOR Q1 2018 IS EXPECTED TO GROW APPROXIMATELY 13% IN RMB TERMS.CHINA BIOLOGIC PRODUCTS HOLDINGS- EXCLUDING TIANXINFU RESULTS, Q1 NON-GAAP ADJUSTED NET INCOME EXPECTED TO DECLINE 12-14% Y-O-Y IN RMB TERMS.CHINA BIOLOGIC - INCLUDING TIANXINFU'S CONTRIBUTION, NON-GAAP ADJUSTED. NET INCOME FOR Q1 2018 IS EXPECTED TO GROW 1% TO 3% YEAR OVER YEAR IN RMB TERMS.CHINA BIOLOGIC - ONGOING REFORM HEADWINDS INITIATED IN 2017 IN CHINA'S HEALTHCARE MARKET FURTHER NEGATIVELY IMPACTED Q1 SALES REVENUE, PROFIT GROWTH.  Full Article

China Biologic Sees FY 2017 Sales Up About 10.5 Pct
Monday, 8 Jan 2018 

Jan 8 (Reuters) - China Biologic Products Holdings Inc ::CHINA BIOLOGIC ANNOUNCES CORPORATE UPDATE.SEES FY 2017 SALES UP ABOUT 10.5 PERCENT.  Full Article

China Biologic posts Q3 adj. earnings per share $1.38
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - China Biologic Products Holdings Inc :China Biologic reports unaudited financial results for the third quarter of 2017.Q3 adjusted non-GAAP earnings per share $1.38.Q3 earnings per share $1.11.Q3 sales rose 15.1 percent to $99.6 million.China Biologic Products Holdings Inc - ‍reiterates full year non-GAAP adjusted net income forecast​.China Biologic Products Holdings - ‍adjusting FY 2017 forecast of total sales growth to 9 pct-10 pct in RMB terms compared to previous estimates of 13 pct-15 pct​.  Full Article

China Biologic agrees to acquire Tianxinfu from PWM
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - China Biologic Products Holdings Inc :China Biologic agrees to acquire Tianxinfu from PWM.China Biologic Products Holdings Inc - ‍It has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd​.China Biologic Products - ‍In exchange for acquisition of 80% equity interest in Tianxinfu from PWM, Cbpo will issue 5.5 million ordinary shares to PWM​.China Biologic Products - ‍PWM is expected to hold approximately 16.66% of outstanding share capital of Cbpo taking into effect new issuance​ post deal.China Biologic Products - Board determined to exempt deal from causing PWM to be deemed "acquiring person" under CBPO's preferred shares rights agreement​.China Biologic Products Holdings Inc - ‍Acquire 80% equity interest in Tianxinfu from PW Medtech Group Limited​.China Biologic Products - ‍CBPO elected to be exempted from shareholder approval requirement under applicable rules of nasdaq market for proposed deal.China Biologic Products Holdings - ‍Elected to be exempted from shareholder approval requirement under applicable rules of Nasdaq stock market for deal.China Biologic Products Holdings Inc - ‍Post deal close, PWM expected to hold about 16.66% of share capital of co taking into effect new issuance​.  Full Article

Photo

Breakingviews - China Biologic suffers contaminated infusion

HONG KONG (Reuters Breakingviews) - China Biologic Products makes a good case for why it should go private. Instead of accepting one of two takeover bids offering hefty premiums, the U.S.-listed manufacturer of plasma products opted for a dilutive share sale at a discount to both. Fuzzy math and poor corporate governance create nothing but bad blood.